News from Dicerna, Auxilium and Essentialis – People on the move
in-PharmaTechnologist presents its weekly round-up of the latest new faces at pharmas and biotechs, including news from Dicerna, Auxilium and Essentialis.
Delivery tech firm MonoSol Rx and nanoparticle excipient developer Midatech have set up a new diabetes-focused joint venture (JV).
Xoma will further reduce its manufacturing capacity with plans to cut a third of its workforce.
Bioligands bought by investors and UK's Bridge BioResearch
Preclinical molecular biology services firm BioLigands has changed ownership.
Biopharm companies have inked a raft of contract service deals at the start of 2012 in efforts to push compounds into the clinic.
Alnylam hails RNAi delivery tech as future of biz after PhI results
Phase I data shows Alnylam a “very potent” RNAi delivery platform that can be the foundation of its future, the company’s CEO said.
The US Food and Drug Administration (FDA) will soon start asking drugmakers to play a greater role in guideline development. Before that process begins in-Pharmatechnologist.com takes a look at the documents published by the agency in 2011.
Kiwi scientists develop resealable drug delivery 'cage'
New Zealand researchers have developed a delivery method in which drugs are transferred to their targets in a resealable 'metallosupramolecular cage'.
Scientists develop temp sensitive cancer drug delivery tech
A new nanostructured polymer can release anti-cancer drugs once it hits body temperature, according to research.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Pall will buy US instrument maker ForteBio next year in a continuation of efforts to build its biomanufacturing technology offering.
Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.
Lonza has expanded small molecule production capacity at its plant in Nansha, China to meet demand for clinical trial materials.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
Frontage and Janssen develop preclinical metformin testing method
Frontage Laboratories has teamed up with Janssen Pharmaceuticals to develop a chromatographic preclinical testing method they say could finally solve metformin development issues.
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
ADC Biotechnology (ADC Bio) has secured a development grant for a new antibody drug conjugate (ADC) manufacturing technology that, it says, can make drug production cheaper.
News from Inviragen, Auxilium, and Icon Biosciences – People on the move
Outsourcing-Pharma presents its weekly round-up of the latest movers and shakers in the pharmaceutical industry, including news from Inviragen, Auxilium, and Icon Biosciences.
Lonza wins preclinical testing contract for ‘virus supressing factor’
Lonza will supply preclinical immunogenicity testing services for a candidate protein antiviral being worked on by South Korean biotech ImmuneMed.
Catalent to add biologics manufacturing capacity with new plant
Catalent says it will increase biologics capacity, joining the growing list of contractors investing in biodrug production.
PhRMA backs FDA plans for biosimilar fees discussion
US drug industry group PhRMA has backed FDA plans to discuss fees for biosimilars with pharmaceutical manufacturers.
News from Takeda, Immune Design, and Pharmacyclics – People on the move
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
Samsung and Quintiles' biosimilars JV teams with Biogen Idec
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
CNS launches custom-fit regulatory consulting service
Clinical Network Services (CNS) has launched its new custom-fit regulatory consulting service, BioDesk.
FDA releases draft co-crystal guidance to support NDAs
The US FDA has published draft guidance to help companies submit marketing applications for API-excipient co-crystals.
News from AstraZeneca, Apricus, and BioTime – People on the move
in-PharmaTechnologist presents its round-up of the latest career moves within the world of pharmaceuticals, including news from AstraZeneca, Apricus, and BioTime.
Lonza to supply Elan with API for trials of candidate Alzheimer’s disease drug
Chemicals supplier Lonza will manufacture the API for a candidate Alzheimer’s disease drug being developed by Elan in an agreement announced yesterday.
Drug delivery research round-up
in-PharmaTechnologist presents its round-up of the latest drug delivery research developments in the pharmaceutical world, including tumour targeting peptides and lipid nanoparticle drug-delivery technology.
News from Genesis, Acino and Pharmalink AB – People on the move
in-PharmaTechnologist presents its weekly line-up of the latest appointments in the pharmaceutical industry, including news from Genesis, Acino and Pharmalink AB.
Covance is adding mass spectrometry and other capabilities to meet growing demand for biosimilar comparability services.
FDA nanomaterial draft guidance means pointless extra regulation, say experts
FDA draft guidance defines nanoparticles too broadly and could result in APIs being categorised as nanomaterials, industry said.
ShangPharma opening facility dedicated to major customer
ShangPharma is opening a 100,000 sq ft facility dedicated to serving a big customer as it continues to strengthen ties to top clients.
News from Genzyme, Catalent and Futura – People on the move
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
Pall sets up Singapore processing COE
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
West inks pre-filled syringe deal with Vetter
Injectable drug delivery systems maker West has struck a new joint venture with Vetter to provide source filled Daikyo Crystal Zenith syringes.
Novozymes rolls out new HA product
Novozymes Biopharma says its new hyaluronic acid has sustainability, safety and production benefits for the pharmaceutical manufacturing sector.
Piramal Healthcare has added commercial-scale antibody-drug-conjugate (ADC) manufacturing capacity at its UK plant predicting increasing demand for this specialist type of contracting.
Using chiral metal surfaces in drug manufacturing could save companies time and money, say researchers at University of Cambridge.
Delivery vehicles can revitalise RNAi sector; AAPS panel
Aptamers and dendrimers can revitalise the faltering siRNA sector by solving delivery problems, AAPS panelists said.
WuXi buys two Chinese CROs in clinical trial expansion
WuXi PharmaTech has expanded into Phase I-IV clinical trial services through the acquisition of two China-based CROs.
News from Novocure, YM BioSciences, and SGVI – People on the move
in-PharmaTechnologist presents its round-up of the latest appointments within the pharmaceutical industry, including news from Novocure, YM BioSciences, and SGVI.
VaxyGen & Georgia State join for protein purification services
VaxyGen is working with Georgia State University (GSU) to offer protein purification, optimisation and production services.
New Hamner - PBM venture says its toxicity testing could save billions in drug discovery
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
Medgenics confirms talks with Baxter on biopump deal
Tissue-based delivery tech developer Medgenics is in talks with Baxter Healthcare about new deal, but says continued focus on Factor VIII is not ‘mission critical’ to biopump platform.
Porcine trypsin guidance may apply retrospectively; EMA
The EMA may apply proposed porcine trypsin guidelines to existing products, such as a GSK vaccine, to cut viral contamination.
Rituximab success paves way for plant produced mAbs
iBio is expanding use of its green plant technology to biosimilar mAbs after producing rituximab using the system.
Dong-A and Meiji Seika to build biosimilars plant
South Korean drugmaker Dong-A and Japan’s Meiji Seika Pharma will build a biosimilars plant in a bid to target the global Ab-based drug market.
CRO sector saw workload, revenues and jobs grow over last decade
The contract research sector has grown markedly over the last decade, with more drugs being examined in more trials by more researchers according to a new Association of Clinical Research Organisations (ACRO) survey.
Aesica plans expansion in US & Asia after investment
CDMO Aesica is to add manufacturing capacity in Asia and the US following a cash injection from private equity firm Silverfleet Capital.